Lymphedema prevalence and treatment benefits in cancer: Impact of a therapeutic intervention on health outcomes and costs

Kimberly M. Brayton, Alan T. Hirsch, Patricia J. O'Brien, Andrea Cheville, Pinar Karaca-Mandic, Stanley G. Rockson

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Lymphedema is a common complication of cancer therapeutics; its prevalence, treatment outcomes, and costs have been poorly defined. The objective of this study was to examine lymphedema prevalence among cancer survivors and to characterize changes in clinical outcomes and costs associated with a defined therapeutic intervention (use of a pneumatic compression devices [PCD]) in a representative, privately insured population. Methods and Findings: Retrospective analysis of de-identified health claims data from a large national insurer for calendar years 2007 through 2013. Patients were required to have 12 months of continuous insurance coverage prior to PCD receipt (baseline), as well as a 12-month follow-up period. Analyses were performed for individuals with cancer-related lymphedema (n51,065). Lymphedema prevalence was calculated: number of patients with a lymphedema claim in a calendar year divided by total number of enrollees. The impact of PCD use was evaluated by comparing rates of a pre-specified set of health outcomes and costs for the 12 months before and after, respectively, PCD receipt. Lymphedema prevalence among cancer survivors increased from 0.95% in 2007 to 1.24% in 2013. PCD use was associated with decreases in rates of hospitalizations (45% to 32%, p,0.0001), outpatient hospital visits (95% to 90%, p,0.0001), cellulitis diagnoses (28% to 22%, p50.003), and physical therapy use (50% to 41%, p,0.0001). The average baseline health care costs were high ($53,422) but decreased in the year after PCD acquisition (-$11,833, p,0.0001). Conclusions: Lymphedema is a prevalent medical condition that is often a defining attribute of cancer survivorship. The problem is associated with high health care costs; Treatment (in this instance, use of PCD) is associated with significant decreases in adverse clinical outcomes and costs.

Original languageEnglish (US)
Article numbere114597
JournalPloS one
Volume9
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Lymphedema
Health Care Costs
Pneumatics
Health
Equipment and Supplies
therapeutics
neoplasms
health care costs
Costs
Neoplasms
physical therapy
Health care
cellulitis
Therapeutics
Survivors
health claims
insurance
Physical therapy
Costs and Cost Analysis
Insurance Carriers

Cite this

Lymphedema prevalence and treatment benefits in cancer : Impact of a therapeutic intervention on health outcomes and costs. / Brayton, Kimberly M.; Hirsch, Alan T.; O'Brien, Patricia J.; Cheville, Andrea; Karaca-Mandic, Pinar; Rockson, Stanley G.

In: PloS one, Vol. 9, No. 12, e114597, 01.12.2014.

Research output: Contribution to journalArticle

Brayton, Kimberly M. ; Hirsch, Alan T. ; O'Brien, Patricia J. ; Cheville, Andrea ; Karaca-Mandic, Pinar ; Rockson, Stanley G. / Lymphedema prevalence and treatment benefits in cancer : Impact of a therapeutic intervention on health outcomes and costs. In: PloS one. 2014 ; Vol. 9, No. 12.
@article{8ed4c98ffe0347668e4cc84591af83d6,
title = "Lymphedema prevalence and treatment benefits in cancer: Impact of a therapeutic intervention on health outcomes and costs",
abstract = "Background: Lymphedema is a common complication of cancer therapeutics; its prevalence, treatment outcomes, and costs have been poorly defined. The objective of this study was to examine lymphedema prevalence among cancer survivors and to characterize changes in clinical outcomes and costs associated with a defined therapeutic intervention (use of a pneumatic compression devices [PCD]) in a representative, privately insured population. Methods and Findings: Retrospective analysis of de-identified health claims data from a large national insurer for calendar years 2007 through 2013. Patients were required to have 12 months of continuous insurance coverage prior to PCD receipt (baseline), as well as a 12-month follow-up period. Analyses were performed for individuals with cancer-related lymphedema (n51,065). Lymphedema prevalence was calculated: number of patients with a lymphedema claim in a calendar year divided by total number of enrollees. The impact of PCD use was evaluated by comparing rates of a pre-specified set of health outcomes and costs for the 12 months before and after, respectively, PCD receipt. Lymphedema prevalence among cancer survivors increased from 0.95{\%} in 2007 to 1.24{\%} in 2013. PCD use was associated with decreases in rates of hospitalizations (45{\%} to 32{\%}, p,0.0001), outpatient hospital visits (95{\%} to 90{\%}, p,0.0001), cellulitis diagnoses (28{\%} to 22{\%}, p50.003), and physical therapy use (50{\%} to 41{\%}, p,0.0001). The average baseline health care costs were high ($53,422) but decreased in the year after PCD acquisition (-$11,833, p,0.0001). Conclusions: Lymphedema is a prevalent medical condition that is often a defining attribute of cancer survivorship. The problem is associated with high health care costs; Treatment (in this instance, use of PCD) is associated with significant decreases in adverse clinical outcomes and costs.",
author = "Brayton, {Kimberly M.} and Hirsch, {Alan T.} and O'Brien, {Patricia J.} and Andrea Cheville and Pinar Karaca-Mandic and Rockson, {Stanley G.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1371/journal.pone.0114597",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Lymphedema prevalence and treatment benefits in cancer

T2 - Impact of a therapeutic intervention on health outcomes and costs

AU - Brayton, Kimberly M.

AU - Hirsch, Alan T.

AU - O'Brien, Patricia J.

AU - Cheville, Andrea

AU - Karaca-Mandic, Pinar

AU - Rockson, Stanley G.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Background: Lymphedema is a common complication of cancer therapeutics; its prevalence, treatment outcomes, and costs have been poorly defined. The objective of this study was to examine lymphedema prevalence among cancer survivors and to characterize changes in clinical outcomes and costs associated with a defined therapeutic intervention (use of a pneumatic compression devices [PCD]) in a representative, privately insured population. Methods and Findings: Retrospective analysis of de-identified health claims data from a large national insurer for calendar years 2007 through 2013. Patients were required to have 12 months of continuous insurance coverage prior to PCD receipt (baseline), as well as a 12-month follow-up period. Analyses were performed for individuals with cancer-related lymphedema (n51,065). Lymphedema prevalence was calculated: number of patients with a lymphedema claim in a calendar year divided by total number of enrollees. The impact of PCD use was evaluated by comparing rates of a pre-specified set of health outcomes and costs for the 12 months before and after, respectively, PCD receipt. Lymphedema prevalence among cancer survivors increased from 0.95% in 2007 to 1.24% in 2013. PCD use was associated with decreases in rates of hospitalizations (45% to 32%, p,0.0001), outpatient hospital visits (95% to 90%, p,0.0001), cellulitis diagnoses (28% to 22%, p50.003), and physical therapy use (50% to 41%, p,0.0001). The average baseline health care costs were high ($53,422) but decreased in the year after PCD acquisition (-$11,833, p,0.0001). Conclusions: Lymphedema is a prevalent medical condition that is often a defining attribute of cancer survivorship. The problem is associated with high health care costs; Treatment (in this instance, use of PCD) is associated with significant decreases in adverse clinical outcomes and costs.

AB - Background: Lymphedema is a common complication of cancer therapeutics; its prevalence, treatment outcomes, and costs have been poorly defined. The objective of this study was to examine lymphedema prevalence among cancer survivors and to characterize changes in clinical outcomes and costs associated with a defined therapeutic intervention (use of a pneumatic compression devices [PCD]) in a representative, privately insured population. Methods and Findings: Retrospective analysis of de-identified health claims data from a large national insurer for calendar years 2007 through 2013. Patients were required to have 12 months of continuous insurance coverage prior to PCD receipt (baseline), as well as a 12-month follow-up period. Analyses were performed for individuals with cancer-related lymphedema (n51,065). Lymphedema prevalence was calculated: number of patients with a lymphedema claim in a calendar year divided by total number of enrollees. The impact of PCD use was evaluated by comparing rates of a pre-specified set of health outcomes and costs for the 12 months before and after, respectively, PCD receipt. Lymphedema prevalence among cancer survivors increased from 0.95% in 2007 to 1.24% in 2013. PCD use was associated with decreases in rates of hospitalizations (45% to 32%, p,0.0001), outpatient hospital visits (95% to 90%, p,0.0001), cellulitis diagnoses (28% to 22%, p50.003), and physical therapy use (50% to 41%, p,0.0001). The average baseline health care costs were high ($53,422) but decreased in the year after PCD acquisition (-$11,833, p,0.0001). Conclusions: Lymphedema is a prevalent medical condition that is often a defining attribute of cancer survivorship. The problem is associated with high health care costs; Treatment (in this instance, use of PCD) is associated with significant decreases in adverse clinical outcomes and costs.

UR - http://www.scopus.com/inward/record.url?scp=84946862586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946862586&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0114597

DO - 10.1371/journal.pone.0114597

M3 - Article

C2 - 25470383

AN - SCOPUS:84946862586

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e114597

ER -